Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M

CORCEPT THERAPEUTICS INC

2021-FY EPS reported $0.89 revenue$365,978,000

Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).
Q4 GAAP net income $32.1M (vs $26M); FY GAAP net income $112.5M (vs $106M). Non-GAAP Q4 $42.6M.
2022 revenue guidance $400-430M, implying 9-17% growth.
Repurchased 10M shares for $207.5M in Q4; cash+investments $335.8M.
Clinical: ovarian cancer Phase 3 start Q2 2022; AIWG Phase 2 data Q4 2022; NDA for Cushing's Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.